543
Participants
Start Date
November 3, 2020
Primary Completion Date
September 30, 2028
Study Completion Date
September 30, 2028
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
6 cycles (21-day cycles)
rituximab and lenalidomide
rituximab 6 cycles and lenalidomide 12 cycles (28-day cycles)
rituximab and bendamustine
6 cycles (28-day cycles)
rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin
3 cycles (21-day cycles)
gemcitabine and oxaliplatin
4 cycles (28-day cycles)
Epcoritamab
Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year.
rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone
6 cycles (21-day cycles)
Lenalidomide
12 cycles (28-day cycles)
rituximab, ifosfamide, carboplatin, and etoposide phosphate
3 cycles (21-day cycles)
Epcoritamab
Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.
Epcoritamab
Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years.
Epcoritamab
Every week in cycle 1 and then every 8 weeks for a total of 2 years.
Epcoritamab
Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8.
Epcoritamab
Every week in cycle 1-3 and then every 4 weeks for a total of 2 years.
Epcoritamab
Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression.
Epcoritamab
"Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules.~Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years.~In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years."
Rituximab and Lenalidomide
Rituximab 375 milligrams per meter squared (mg/m\^2) will be administered intravenously QW in Cycle 1 and Q4W in Cycles 2-5. Lenalidomide 20 mg will be administered orally daily for 21 days for 12 cycles.
Epcoritamab
Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity.
Oslo Universitetssykehus HF, Radiumhospitalet, Oslo
Rigshospitalet, Copenhagen
UMC Utrecht, Utrecht
CHU UCL Namur Site Godinne, Yvoir
Linear Clinical Research Limited, Nedlands
AZ Sint-Jan, Bruges
Hospital Universitari Vall d'Hebron, Barcelona
Universitair Ziekenhuis Gent, Ghent
Universitair Medisch Centrum Groningen (UMCG), Groningen
Mount Sinai, New York
Fondazione del Piemonte per l Oncologia Istituto di Candiolo IRCCS, Candiolo
Memorial Sloan Kettering CC, New York
Hôpital de la Timone, Marseille
Fakultni nemocnice v Motole, Prague
HUS Cancer Center, Lahti
Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico, Milan
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII), Bergamo
Fondazione IRCCS Policlinico San Matteo, Pavia
Hospital Universitario Fundacion Jimenez Diaz, Madrid
Hospital Universitario La Paz, Madrid
Levine Cancer Center, Charlotte
University of Alabama at Birmingham, Birmingham
Hospital Universitario de Salamanca, Salamanca
Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia, Reggio Emilia
IRCCS Istituto Scientifico Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST, Meldola
University of Michigan Comprehensive Cancer Center Michigan Medicine, Ann Arbor
Hopital Claude Huriez - CHRU Lille, Lille
Centre Hospitalier Lyon Sud, Pierre-Bénite
Kuopio University Hospital, Kuopio
Southwestern Medical Center, Dallas
Hôpital Saint-Louis, Paris
Cedars-Sinai Medical Center, Los Angeles
David Geffen School of Medicine at UCLA, Los Angeles
University of California San Francisco, San Francisco
Dana Farber Cancer Institute, Boston
Hackensack University Medical Center, Hackensack
Austin Health, Heidelberg
Fakultni nemocnice Hradec Kralove, Hradec Králové
Fakultni nemocnice Ostrava, Ostrava - Poruba
Vseobecna Fakultni Nemocnice, Prague
Århus Hospital, Aarhus
Odense University Hospital, Odense
Vejle Sygehus, Vejle
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS, Bologna
Erasmus Medisch Centrum, Rotterdam
Södra Älvsborgs Sjukhus, Borås
Skånes Universitetssjukhus, Lund
Karolinska Universitetssjukhuset, Solna
Akademiska Sjukhuset, Uppsala
The Christie Hospital, Manchester
Amsterdam UMC, Locatie VUMC, Amsterdam
Leids Universitair Medisch Centrum, Leiden
Maastricht University Medical Center, Maastricht
ICO l Hospitalet, Barcelona
Sahlgrenska Sjukhuset, Gothenburg
Freeman Hospital, Newcastle upon Tyne
Derriford Hospital, Plymouth